Beneficial Effect of Low Ethanol Intake on the Cardiovascular System: Possible Biochemical Mechanisms by Vasdev, Sudesh et al.
Vascular Health and Risk Management 2006:2(3) 263–276
© 2006 Dove Medical Press Limited. All rights reserved
263
REVIEW
Abstract: Low ethanol intake is known to have a beneficial effect on cardiovascular disease.
In cardiovascular disease, insulin resistance leads to altered glucose and lipid metabolism
resulting in an increased production of aldehydes, including methylglyoxal. Aldehydes react
non-enzymatically with sulfhydryl and amino groups of proteins forming advanced glycation
end products (AGEs), altering protein structure and function. These alterations cause
endothelial dysfunction with increased cytosolic free calcium, peripheral vascular resistance,
and blood pressure. AGEs produce atherogenic effects including oxidative stress, platelet
adhesion, inflammation, smooth muscle cell proliferation and modification of lipoproteins.
Low ethanol intake attenuates hypertension and atherosclerosis but the mechanism of this
effect is not clear. Ethanol at low concentrations is metabolized by low Km alcohol
dehydrogenase and aldehyde dehydrogenase, both reactions resulting in the production of
reduced nicotinamide adenine dinucleotide (NADH). This creates a reductive environment,
decreasing oxidative stress and secondary production of aldehydes through lipid peroxidation.
NADH may also increase the tissue levels of the antioxidants cysteine and glutathione, which
bind aldehydes and stimulate methylglyoxal catabolism. Low ethanol improves insulin
resistance, increases high-density lipoprotein and stimulates activity of the antioxidant enzyme,
paraoxonase. In conclusion, we suggest that chronic low ethanol intake confers its beneficial
effect mainly through its ability to increase antioxidant capacity and lower AGEs.
Keywords: low ethanol, hypertension, cardiovascular disease, biochemical mechanisms,
advanced glycation end products
Introduction
Ethanol intake is a common lifestyle factor found across many cultures and geographic
regions. Since cardiovascular disease is also found ubiquitously and accounts for
more than 16 million deaths per year worldwide, it is essential to understand how
they relate to each other (WHO 2003a). Various epidemiological and controlled
clinical studies have investigated the effects of varying levels and patterns of ethanol
intake on cardiovascular health (Reynolds et al 2003; Corrao et al 2004). In contrast
to high ethanol intake which is detrimental to cardiovascular health, chronic low
ethanol has been shown to have a beneficial effect (Camargo et al 1997; Okubo et al
2001; Corrao et al 2004; Piano 2005). Understanding the biological mechanism of
this beneficial effect will aid in identifying potential preventative or therapeutic agents.
In this review, we discuss the factors involved in the development and progression
of cardiovascular disease and the possible biochemical mechanisms by which low
ethanol counters these factors to prevent or attenuate this disease.
Cardiovascular disease
Cardiovascular disease includes atherosclerosis and hypertension. Hypertension
affects more than 600 million people worldwide and results in 13% of the total deaths
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globally (WHO 2003b). Approximately 90% of all
hypertension is classified as “essential” meaning that the
cause is not known. Essential hypertension involves
endothelial dysfunction with alterations in nitric oxide (NO)
bioavailability and calcium handling, smooth muscle cell
proliferation, thickening of the vessel walls, and increased
peripheral vascular resistance and blood pressure (Resnick
1993; Oshima and Young 1995; Taddei et al 2003; Portaluppi
et al 2004). Risk factors for hypertension include family
history, diabetes, obesity, smoking, excessive alcohol intake,
and a diet high in salt and/or low in antioxidant nutrients.
Most of these risk factors are modifiable through lifestyle
changes such as participating in moderate physical activity
and eating a well-balanced diet. Healthy lifestyle choices
also include not smoking and limiting alcohol intake (WHO
2003b). Individuals with hypertension are at increased risk
for atherosclerotic diseases such as stroke, and heart and
kidney disease.
Atherosclerosis is a leading cause of death in the world.
Heart disease and stroke are the two leading causes of death
in adults in developed countries and are responsible for a
third of all deaths in developing countries (WHO 2003a).
Atherosclerosis is an inflammatory condition of the blood
vessels (Ross 1999). Damage to, or activation of, the
endothelium promotes entry of modified low-density
lipoprotein (LDL) into the intima, a process enhanced by
an elevation in circulating levels of LDL. Alteration in
endothelium also increases the expression of adhesion
molecules on the cell surface resulting in recruitment of
monocytes and platelet adhesion. The monocytes
transmigrate to the sub-endothelial space where they
differentiate into macrophages. Modified LDL is scavenged
by macrophages in the interstitial space transforming over
time into foam cells. Accumulation of foam cells and other
cellular debris evolve into atherosclerotic plaques
(Chakarvarti et al 1991; Witztum and Steinberg 1991;
Palinski et al 1995; Ross 1999; Sima and Stancu 2002;
Hansson 2005). Although atherosclerotic lesions generally
occur at junctions of large- and medium-size vessels, they
may also arise throughout the vasculature (Tegos et al 2001;
Hansson 2005). Through stenosis or embolytic occlusion,
lesions within the coronary, cerebral, peripheral or renal
vessels result in the clinical manifestations of angina,
myocardial infarction, stroke, peripheral arterial disease or
renal failure (Tegos et al 2001). Atherosclerosis also involves
increased smooth muscle cell migration and proliferation.
Stiffening of the vessel walls may hinder elasticity
exacerbating hypertension. Hypertension is considered a risk
factor for atherosclerosis, as increased blood pressure itself
can contribute to vascular injury, making vessels more
susceptible to inflammation (Chobanian and Alexander
1996). However, studies show that lowering blood pressure
alone does not completely eliminate the risk of
cardiovascular disease (Neutel 2000). Other risk factors
include smoking, diabetes mellitus, obesity, dyslipidemias,
and a diet high in saturated fat (WHO 2003a, 2003b).
Hypertension and atherosclerosis share similar risk factors
and both are characterized by modified vascular structure
and function (Pepine and Handberg 2001). These
cardiovascular conditions are also linked by another




We suggest that the key etiological factor in cardiovascular
disease is insulin resistance (Figure 1). Insulin resistance is
characterized by an inadequate glucose uptake in peripheral
tissues at a given concentration of plasma insulin. It involves
an impairment of the nonoxidative (glycolytic) pathways
of intracellular glucose metabolism (Ferrannini et al 1987).
Insulin resistance has been well documented in hypertension
and atherosclerosis. Humans with essential hypertension and
normotensive offspring of essential hypertensives have
insulin resistance (Ferrannini et al 1987; Saad et al 2004;
Vlasakova et al 2004). Abnormalities in glucose metabolism
exist in up to 80% of subjects with essential hypertension
(Ferrannini et al 1987; Flack and Sowers 1991). Insulin
resistance has also been documented in humans with
atherosclerosis (DeFronzo and Ferrannini 1991; Howard et
al 1996; Shinozaki et al 1996; Reaven 2003). It has been
suggested that hypertensives who are insulin resistant are
at increased risk for atherosclerotic disease (Reaven 2003;
Liao et al 2004). In metabolic syndrome, also known as
syndrome X or insulin resistance syndrome, primary insulin
resistance is linked to a group of co-existing conditions
including hypertension, dyslipidemias, diabetes, and
atherosclerotic cardiovascular disease (DeFronzo and
Ferrannini 1991).
Aldehydes
Under normal physiological conditions, glucose is
metabolized via the glycolytic pathway to glyceraldehyde-
3-phosphate (G3P) which is converted to 1,3-
diphosphoglycerate by the enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), with furtherVascular Health and Risk Management 2006:2(3) 265
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metabolism to pyruvate. Any factor which affects GAPDH,
whether through inhibition or upregulation, has an impact
on the rate of glucose metabolism. It has been shown that
GAPDH is upregulated by insulin (Alexander et al 1988).
In insulin resistant states, altered insulin function may down-
regulate GAPDH, slowing glucose metabolism through the
glycolytic pathway, thus increasing metabolism via the
polyol pathway. This may result in a build-up of G3P leading
to an increase in the highly reactive aldehyde, methylglyoxal
(Mayes 1983; Thornalley 1993; Beisswenger et al 2003).
Methylglyoxal itself has been shown to inhibit GAPDH,
resulting in further abnormalities in glucose metabolism
(Morgan et al 2002). Methylglyoxal also induces aldose
reductase which is known to stimulate flux of glucose
through the polyol pathway with further formation of
methylglyoxal (Chang et al 2002). An excess of dietary sugar
or fat, or both, typical of western diets, may overload these
pathways and exacerbate this altered metabolism. Insulin
resistance is also associated with dyslipidemia (Fuh et al
1987; Liao et al 2004); elevated LDL without the mitigating
antioxidant effect of high high-density lipoprotein (HDL),
may contribute to an increase in reactive aldehydes (Dargel
1992).
Advanced glycation end products
Advanced glycation end products (AGEs) are formed when
aldehydes (eg, methylglyoxal, glyoxal, glucose) react
nonenzymatically with free sulfhydryl (SH) and amino
(NH2) groups of amino acids including cysteine, arginine
or lysine, of proteins (Schauenstein et al 1977; Thorpe and
Baynes 2003; Thornalley et al 2003). This direct
modification of protein structure results in functional
changes (Morgan et al 2002; Nagaraj et al 2002; Karachalias
et al 2003). AGE-modified protein has also been shown to
stimulate receptors of AGEs (RAGEs) and various scavenger
receptors to influence protein function and expression
(Schmidt et al 2001; Wautier et al 2001; Horiuchi et al 2003).
Normally, methylglyoxal is formed but kept at a low level
through catabolism via the glutathione-dependent
glyoxalase enzyme system or by binding to cysteine and
being excreted in bile and urine (Schauenstein et al 1977).
It has been suggested that AGEs formed in low
concentrations contribute to the regulation of normal tissue
remodeling (Kirstein et al 1992) but when found in excess
are pathogenic (Vasdev et al 2000a, 2000b; Mizutani et al
2002; Alderson et al 2003; Bidasee et al 2003; Karachalias
et al 2003; Stitt et al 2004; Vasdev et al 2005). It has also
been proposed that certain AGEs have normal biological
functions whereas others referred to as toxic AGEs, play a
pathophysiological role (Takeuchi and Yamagishi 2004).
Whatever the case, several specific AGEs including
carboxymethyl-lysine, carboxyethyl-lysine, argpyrimidine,
and glycoaldehyde-pyridine, have been identified, and have
been implicated in the pathology of hypertension and
atherosclerosis (Anderson et al 1999; Oya et al 1999; Baynes
and Thorpe 2000; Nagai et al 2002; Alderson et al 2003;
Wang et al 2004).
Causative role of advanced glycation end products
in cardiovascular disease
It is known that AGEs act directly or via receptors to alter
the function of cellular proteins including calcium channels,
metabolic and antioxidant enzymes, receptors and structural
Figure 1 Mechanism of cardiovascular disease. In insulin resistant state, excess
aldehydes formed due to altered glucose/lipid metabolism react with proteins to
form advanced glycation end products (AGEs). AGEs alter the functions of
cellular proteins including vascular ion channels, and metabolic and antioxidant
enzymes, with oxidative stress leading to hypertension and atherosclerosis.Vascular Health and Risk Management 2006:2(3) 266
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proteins leading to endothelial dysfunction, inflammatory
responses, and increased oxidative stress (Figure 2). Thus,
it is becoming increasingly clear that AGEs play a major
causative role in hypertension and atherosclerosis. We have
shown that methylglyoxal given in the diet to Wistar-Kyoto
(WKY) rats increased tissue AGEs and caused hypertension
(Vasdev et al 1998). Levels of tissue methylglyoxal and
AGEs are higher in spontaneously hypertensive rats (SHR)
and sugar-induced hypertensive rats (Vasdev et al 2000a,
2000b; Wu and Juurlink 2002; Midaoui et al 2003; Wang et
al 2004). Although research on AGEs in human essential
hypertension is scant, in preeclampsia, a hypertensive
condition of pregnancy, RAGE expression was increased
in vascular tissue (Cooke et al 2003). AGE-mediated
crosslinks in collagen and elastin, also contribute to arterial
stiffening, hindering vessel elasticity, and exacerbating
hypertension (Aronson 2003). There is strong evidence in
diabetes, another insulin resistant state, that AGEs are
responsible for cellular protein modifications which
contribute to diabetic atherosclerotic complications
(Kislinger et al 2001; Degenhardt et al 2002; Nagaraj et al
2002; Babaei-Jadidi et al 2003; Karachalias et al 2003; Alt
et al 2004; Stitt et al 2004). Evidence supporting the concept
that AGEs are involved in the etiology of cardiovascular
disease shows that compounds which lower AGEs also lower
blood pressure and attenuate atherosclerotic conditions
(Vasdev et al 2000a, 2000b, 2002; Kislinger et al 2001;
Degenhardt et al 2002; Mizutani et al 2002; Alderson et al
2003; Babaei-Jadidi et al 2003; Midaoui et al 2003;
Sakaguchi et al 2003; Smit and Lutgers 2004; Stitt et al
2004).
Vascular dysfunction
Maintaining normal endothelial function is essential to blood
pressure homeostasis and vessel integrity. One of the major
factors involved in regulation of endothelial function is NO.
Endothelium derived NO is not only a potent vasodilator
but it inhibits platelet aggregation, vascular smooth muscle
cell (VSMC) proliferation and intimal migration, and
monocyte adhesion, thus regulating blood pressure and
Figure 2 Atherosclerotic and hypertensive effects of advanced glycation end products (AGEs) on blood vessels. AGEs act directly and via receptors of AGEs (RAGES)
to alter the function of cellular proteins including calcium channels, endothelial nitric oxide synthase (eNOS), antioxidant enzyme superoxide dismutase (SOD)
resulting in a decrease in NO and an increase of reactive oxygen species (ROS), cytokines, imflammation, platelet aggregation and vascular smooth muscle cell
(VSMC) proliferation. AGEs and ROS also modify low density lipoprotein (LDL) increasing uptake by macrophages contributing to the formation of plaque. These
alterations lead to hypertension and atherosclerosis.Vascular Health and Risk Management 2006:2(3) 267
Low ethanol intake and the cardiovascular system
protecting vascular function (Taddei et al 2003).
Abnormalities in NO have been demonstrated in both
hypertension and atherosclerosis (Taddei et al 2003;
Shinozaki et al 2004).
The ability of vascular tissue to form adequate amounts
of NO depends on the availability of its substrate, arginine,
and the endothelial enzyme, nitric oxide synthase (eNOS)
(Taddei et al 2003). Methylglyoxal reacts with arginine
residues to form several AGEs including argpyrimidine
(Shamsi et al 1998; Oya et al 1999; Thornalley et al 2003),
which may limit substrate availability (Degenhardt et al
2002). eNOS is an SH-dependent enzyme with a cysteine
residue identified at its active site (Chen et al 1994). AGEs
have been shown to inhibit eNOS activity and expression
(Verbeke et al 2000; Rojas et al 2000). We have shown that
methylglyoxal given in the diet to WKY rats increased tissue
AGEs and decreased plasma NO (Vasdev et al 1998). NO
production is also regulated by insulin acting on specific
receptors on the cell surface (Trovati et al 1997; Kahn et al
2000). In insulin resistant states, aldehydes may alter
receptor function decreasing NO formation (Sechi et al
1996; Vasdev et al 1998, 2005). NO has a very short half
life. Under physiological conditions, it has been shown to
readily react with SH groups of plasma proteins forming
biologically stable adducts (S-nitrosothiols) which represent
a pool of available NO. Low molecular weight thiols such
as cysteine and glutathione act as transfer agents for NO
from these pools to NO’s site of action (Scharfstein et al
1994; Alencar et al 2003). Since aldehydes also readily react
with SH groups, this suggests a competitive role limiting
both protein binding sites and transfer agent availability
resulting in an increase in NO degradation and possible
endothelial dysfunction (Farkas and Menzel 1995; Thorpe
and Baynes 2003).
Vascular calcium channels are dependent on SH groups
for normal function (Schauenstein et al 1977; Zaidi et al
1989) and their alteration can lead to increased cytosolic
free calcium, abnormal contractile activity and increased
peripheral vascular resistance. AGEs impair type 2
ryanodine receptor calcium release channels (calcium
receptors which regulate cardiac contractility) during
chronic diabetes (Bidasee et al 2003) and AGE-modified
protein increases intracellular calcium (Scivattaro et al
2000). We have shown increased vascular AGEs and platelet
cytosolic free calcium in SHRs, a genetic model of
hypertension and in methylglyoxal- and fructose-treated
WKY rats, dietary models of hypertension (Vasdev et al
1998, 2000a, 2000b).
Since calcium plays a key role in platelet activation,
elevated intracellular free calcium may contribute to the
enhanced platelet aggregation seen in hypertension and
atherosclerosis (Ding 1996). AGEs may also contribute to
platelet aggregation and thrombus formation. AGEs
increased superoxide production and aggregation in human
platelets in vitro (Hangaishi et al 1998). It has been suggested
that AGEs stimulate externalization of phosphatidylserine
which activates clotting factors leading to platelet adhesion
(Wang et al 2005).
Oxidative stress
Under normal physiological conditions, reactive oxygen
species (ROS) are produced in low concentrations and act
as signaling molecules to regulate VSMC contraction-
relaxation, and VSMC growth (Touyz and Schiffrin 2004).
Oxidative stress occurs when ROS outweigh the body’s
antioxidant capacity. Oxidative stress is controlled in part
by antioxidant enzymes, including glutathione peroxidase
and glutathione reductase (Kaul et al 1993). These enzymes
have SH and NH2 groups at their active sites and AGEs
inhibit their activity increasing oxidative stress (Morgan et
al 2002; Wu and Juurlink 2002; Park et al 2003). Excess
ROS can lead to the secondary production of aldehydes such
as malondialdehyde and hydroxynonenal, through lipid
peroxidation (Brooks and Klamerth 1968; Schauenstein et
al 1977; Benedetti et al 1980; Thornalley et al 1984; Dargel
1992; Touyz and Schiffrin 2004). These lipid-derived
aldehydes have been shown to react with cysteine or lysine
residues of proteins to form a type of AGE known as
advanced lipoxidation end products (ALEs) (Baynes and
Thorpe 2000; Thorpe and Baynes 2003; Stitt et al 2004).
There is strong evidence that oxidative stress contributes
to the progression of essential hypertension and the
development of atherosclerosis (Chakravarti et al 1991;
Kumar and Das 1993; Chobanian and Alexander 1996;
Stocker and Keaney 2004; Touyz and Schiffrin 2004).
Oxidative modification of LDL increases uptake by
macrophages via scavenger receptors (further discussed in
dislipidemia section). This results in an increased production
and accumulation of foam cells in the vascular intima leading
to the formation of atherosclerotic lesions. Oxidized LDL
also stimulates atherogenic processes including
inflammation, platelet aggregation, and VSMC proliferation
(Ross 1999; Stocker and Keaney 2004; Hansson 2005).
Oxidative stress impairs endothelial function. ROS
promote uncoupling of eNOS resulting in a decreased
production of NO (Alp and Channon 2004; Shinozaki et alVascular Health and Risk Management 2006:2(3) 268
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2004). ROS also react directly with NO, forming
peroxynitrite, also known as reactive nitrogen species.
This not only limits NO bioavailability, but peroxynitrite
and peroxynitrous acid are powerful and cyto-toxic
oxidants which may cause damage to vascular tissue
(Beckman and Koppenol 1996). Methylglyoxal and AGEs
have been shown to increase oxidative stress (Anderson
et al 1999; Scivittaro et al 2000; Wautier et al 2001;
Mizutani et al 2002; Wu and Jurrlink 2002; Midaoui et
al 2003; Wong et al 2003) and in VSMC in vitro induced
significant generation of superoxide radical and
peroxynitrite (Chang et al 2005).
Dyslipidemia
Dyslipidemia has long been associated with atherosclerosis,
and controlling elevated cholesterol and abnormal
lipoprotein ratios is a recognized preventative cardiovascular
health strategy (Fodor et al 2000). It is well known that
high levels of HDL offer protective cardiovascular effect,
and that elevated LDL is associated with higher risk of
cardiovascular disease.
However, the roles of these lipoproteins are complex
and have not yet been fully elucidated. It has been proposed
that in its native state LDL is not atherogenic but becomes
so under conditions where its structure is modified (Figure
2). Alterations to lysine residues of apolipoprotein B of LDL
result in a decreased binding by LDL receptors and an
increased stimulation of macrophage scavenger receptors
(Witztum and Steinberg 1991; Haberland et al 1992;
Horiuchi et al 2003). Oxidatively modified LDL initiates
atherogenic processes including inflammation, platelet
aggregation and smooth muscle cell proliferation (Stocker
and Keaney 2004). Oxidized LDL has been identified as a
main component in atherosclerotic lesions, and hypertensive
subjects exhibit an enhanced susceptibility to LDL oxidation
(Witztum and Steinberg 1991; Maggi et al 1993).
AGEs can form on lipoproteins themselves and AGE-
LDL has been shown to have similar atherogenic properties
as oxidized LDL (Figure 2). AGE-LDL and AGE-modified
protein are ligands for class AI/AII scavenger receptors
(Horiuchi et al 2003). Binding to these receptors leads to
endocytic uptake of LDL and accumulation in human
monocytes-macrophages (Haberland et al 1992; Horiuchi
et al 2003). AGE-LDL has been identified in the cytoplasm
of foam cells and extracellularly in the core of atherosclerotic
lesions in humans and animals (Palinski et al 1995; Nagai
et al 2002; Sima and Stancu 2002).
HDL’s function in reverse cholesterol transport plays a
key role in its cardioprotective effect. HDL removes
cholesterol from vascular tissue and either transfers it to
very low density lipoprotein (VLDL) or LDL for transport
to the liver, or it carries cholesterol directly to the liver where
it may be recycled or excreted. In dyslipidemia, where HDL
is low, cholesterol may be left to accumulate in vascular
tissue. It has been suggested that AGEs interfere with reverse
cholesterol transport by suppressing scavenger receptor B1
(SR-B1)-mediated uptake of cholesterol ester from HDL
by liver and SR-B1-mediated cholesterol efflux from
peripheral cells (Horiuchi et al 2003). AGEs have been
shown to cause cholesterol and cholesterol ester
accumulation in macrophages in vitro (Brown et al 2005).
HDL also has antioxidant ability. It is closely associated
with the antioxidant enzyme paraoxonase. Low HDL and
paraoxonase levels are associated with oxidative stress,
hypertension and coronary heart disease (Suh et al 1992;
Mackness et al 2001; Uzun et al 2004; Mancia et al 2005).
Paraoxonase protects both HDL and LDL from oxidation
and lipid peroxidation (Aviram, Rosenblat, et al 1998;
Aviram, Billecke, et al 1998; Rao et al 2003). In vitro studies
show that paraoxonase lowers levels of oxidized LDL by
converting them to biologically inactive products (Rao et
al 2003). Blockage of free SH groups (cysteine residues) of
paraoxonase reduced its ability to protect LDL from
oxidation (Aviram, Billecke, et al 1998) suggesting a
possible inhibitory role for AGEs (Hedrick et al 2000;
Ferretti et al 2006).
HDL has also been shown to have antiinflammatory
properties. It inhibited cytokine-induced expression of
adhesion proteins and reduced neutrophil infiltration into
the wall of injured arteries (Barter et al 2004). AGE-
modification of HDL resulted in a loss of these anti-
inflammatory properties (Hedrick et al 2000; Ferretti et al
2006).
Low ethanol intake
Effect on hypertension and
atherosclerosis
It has been well documented that excessive alcohol intake
can be detrimental to cardiovascular health (Thun et al 1997;
Reynolds et al 2003; Corrao et al 2004). Although some
studies of ethanol intake of greater than 30 g/day have shown
improvement in cardiovascular risk, this level of intake
increases risk of other diseases and death by other means
(Camargo et al 1997; Fagrell et al 1999). Therefore, we haveVascular Health and Risk Management 2006:2(3) 269
Low ethanol intake and the cardiovascular system
focused our attention in this review on the effects of low
ethanol intake (Table 1). Since there is no standard definition
of “low” ethanol intake, we have chosen a level of up to,
and including, 24 g per day (equivalent to 2 drinks), for the
purposes of this discussion. A drink has been defined as a
12 oz bottle or can of beer (4%–5% ethanol), a 4 oz glass of
table wine (10%–12% ethanol), or a 1–1.5 oz shot of liquor
or spirits (40% ethanol) (Ellison et al 2004).
Table 1 Effect of low ethanol on hypertension and atherosclerosis
Subject Description Result Reference
Animal
New Zealand white rabbits 0.5% ethanol given in drinking • Reduced neointimal proliferation, Merritt et al 1997
water for 10 weeks  the extent of lipid oxidation and
number of foam cells
Spontaneously hypertensive rats 0.5% ethanol given in drinking • Decreased SBP, cytosolic free calcium, Vasdev et al 1999
water for 14 weeks tissue AGEs, & renal vascular changes
Human
New Zealand males and females, Epidemiologic study of 1429 • U-shaped response of BP to ethanol Jackson et al 1985
35–64 yrs subjects on the effect of ethanol consumption 
consumption on BP • Both light(>0–9 g/day) and moderate
(10–34 g/day) ethanol consumption
lowered SBP and DBP
US males and females  Study of 129 170 individuals • Consumption of 1–2 drinks/day Klatsky et al 1990
undergoing health examinations lowered relative risk of all-cause and
in a prepaid health plan CV mortality
US males and females, 30–104 yrs 9-year prospective study of • 30%–40% decrease in CV death in Thun et al 1997
490 000 subjects on the effect men consuming at least 1 drink/day
of ethanol consumption on • 1 drink/day reduced all-cause
CV and total mortality mortality in men and women
US male physicians, 40–84 yrs 10.7-year prospective study of • Consumption of 2–6 drinks/week Camargo et al 1997
22 071 subjects on the effect resulted in a decreased risk in
of ethanol consumption on all-cause mortality (mostly a result
mortality of a 34%–53% decrease in risk of
CV mortality)
Bulgarian males & females, Study of 155 individuals • J-shaped response with consumption Genchev et al 2001
45–69 yrs hospitalized with ischemic of both light (0.01–18 g/day) and
heart disease (IHD) versus moderate (18.01–36 g/day) ethanol
154 normal control patients associated with a decreased risk of
IHD
Japanese normotensive males, A 5-year observational study of • J-shaped response of BP to ethanol Okubo et al 2001
40–54 yrs 2143 subjects on the effect of consumption 
ethanol consumption on BP • Consumption of <18 ml/day of ethanol
decreased SBP and DBP
Males and females from Meta-analysis of 35 observational • J-shaped response of ischemic stroke Reynolds et al 2003
various countries studies of varying duration and consumption of <12 g/day of
examining the risk of stroke at ethanol associated with a reduced
various levels of alcohol risk of total and ischemic stroke
consumption
Diabetic males and females, Study of 216 subjects hospitalized • J-shaped response with BP, cholesterol, Pitsavos et al 2004
45–75 yrs with first event of ACS versus and risk of ACS and consumption
196 diabetic controls of <12 g/day associated with a 47%
reduction of prevalence of ACS
Males and females from various Meta-analysis of 116 702 subjects • J-shaped response with consumption Corrao et al 2004
countries from 156 epidemiologic studies of 20 g/day of ethanol was estimated
examining the risk of alcohol to provide a 20% reduction in risk of
related diseases and injuries at coronary heart disease
various levels of alcohol
consumption 
Abbreviations: ACS, acute coronary syndrome; AGEs, advanced glycation end products; CV, cardiovascular; BP, blood pressure; DBP, dystolic blood pressure; SBP,
systolic blood pressure.Vascular Health and Risk Management 2006:2(3) 270
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We have shown in rat models of hypertension that
chronic low ethanol is effective in decreasing blood pressure
(Vasdev et al 1999). Two studies of low ethanol intake in
humans, one using up to 9 g/day and the other up to 18 g/
day, showed antihypertensive effects (Jackson et al 1985;
Okubo et al 2001). Most animal research that looked
specifically at atherosclerotic vascular changes, used
moderate to high levels of ethanol. However, one study
which fed low ethanol to an atherosclerotic model of rabbit
showed that it attenuated atherosclerosis with a decrease in
the extent of neointimal proliferation, lipid oxidation, and
number of foam cells (Merritt et al 1997). In humans, low
ethanol consumption reduced risk for both cardiovascular
and non-cardiovascular mortality (Klatsky et al 1990;
Camargo et al 1997; Thun et al 1997) and was associated
with a significantly reduced risk of stroke (Reynolds et al
2003) and ischemic heart disease (Genchev et al 2001). In
diabetic patients, low ethanol intake was associated with a
47% reduction in the prevalence of acute coronary syndrome
(Pitsavos et al 2005) and in individuals known to be at risk
for cardiovascular disease, a 20% reduction in risk of
coronary artery disease (Corrao et al 2004).
Mechanism of beneficial effect
Low ethanol has been shown to improve the clinical
manifestations of cardiovascular disease (Table 1), but what
is the biochemical mechanism of this beneficial effect? We
suggest that low ethanol intake has the ability to increase
antioxidant capacity, improve insulin resistance and decrease
AGEs, thus preventing subsequent hypertensive and
atherosclerotic consequences. To begin, we need to
understand the metabolism of ethanol (Figure 3). Ethanol
is metabolized differently at high and low concentrations.
With chronic high ethanol intake, the microsomal ethanol
Figure 3 Metabolism of high versus low concentrations of ethanol. In high concentrations, ethanol is metabolized by the microsomal ethanol oxidizing system
(MEOS) system. In this reaction, reduced nicotinamide adenine dinucleotide phosphate (NADPH) is converted to oxidized nicotinamide adenine dinucleotide
phosphate (NADP
+) creating an oxidative environment. In low concentrations, ethanol is metabolized by the enzymes alcohol and aldehyde dehydrogenase producing
reduced nicotinamide adenine dinucleotide (NADH) from oxidized nicotinamide adenine dinucleotide (NAD
+) by both reactions, increasing antioxidant capacity. At
the low levels produced, acetate, which is a normal metabolite of glucose and fatty acid metabolism, is further metabolized in the citric acid cycle.Vascular Health and Risk Management 2006:2(3) 271
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oxidizing system (MEOS) is induced. MEOS has a relatively
high Km for ethanol, and at high concentrations ethanol is
metabolized to acetaldehyde without producing reduced
nicotinamide adenine dinucleotide (NADH). Instead, this
pathway utilizes reduced nicotinamide adenine dinucleotide
phosphate (NADPH), another reducing equivalent, thus
producing an oxidative environment (Lieber 1990).
Additionally, chronic high ethanol consumption inhibits
aldehyde dehydrogenase resulting in a significant decrease
in the ability of rat mitochondria to oxidize acetaldehyde.
This high ethanol intake thus associated with an enhanced
rate of metabolism by the MEOS pathway resulting in a
decrease in reducing equivalents, elevated acetaldehyde, and
increased oxidative stress. These factors may account for
the detrimental effects of high ethanol intake. However, at
low ethanol blood levels, ethanol is metabolized very
efficiently by low Km alcohol dehydrogenase to
acetaldehyde and then by aldehyde dehydrogenase to
acetate, producing NADH in both reactions (Lieber 1990;
Bello et al 1994). NADH has a major influence on total
antioxidant capacity of the body. NADH is a key component
of the electron transport chain and, due to its high reducing
potential functions to promote regeneration of endogenous
vitamin radicals back to their reduced form (Figure 4).
Although ethanol is primarily metabolized in the liver, it is
also metabolized in other tissues, including vascular tissue.
This ability of ethanol at low concentrations to create a
strong reducing environment, possibly at the site of
atherosclerotic activity, may enhance its cardiovascular
protective effect.
An increase in antioxidant capacity would offer
protection against oxidative stress (Figures 4 and 5) and
secondary production of aldehydes through lipid
peroxidation (Bello et al 1994). In vitro, ethanol has been
shown to act as an antioxidant by decreasing the rate of
consumption of LDL antioxidants and reducing the
formation of lipid peroxides (Bonnefont-Rousselot et al
2001). In humans, it decreased urinary 8-
hydroxydeoxyguanosine, a measure of oxidative stress
(Yoshida et al 2001). NADH treatment has been shown
to reduce blood pressure and lipid peroxidation in SHRs
(Bushehri et al 1998). NADH may also increase overall
antioxidant capacity, increasing tissue levels of cysteine
by converting cystine to cysteine, via the NADH
dependent enzyme, cystine reductase (Rodwell 1983).
Cysteine is a precursor of glutathione, a major
endogenous antioxidant. Additionally, glutathione is a
cofactor in methylglyoxal catabolism and cysteine has
the ability to bind aldehydes to foster excretion and
reduce AGE formation (Schauenstein et al 1977; Vasdev
et al 1998).
An increase in the low molecular weight thiols, cysteine
and glutathione, may also enhance the transfer of NO from
protein-bound reserves improving endothelial dysfunction
(Scharfstein et al 1994). Decreasing levels of AGEs may
also preserve eNOS and prevent breakdown of NO. Low
ethanol increased the expression of eNOS (Venkov et al
1999) and stimulated calcium-activated potassium channels
increasing production of NO in vascular endothelial cells
in culture (Kuhlmann et al 2004). Humans consuming low
amounts of ethanol showed significant dilatation of brachial
artery at rest and at reactive hyperaemic conditions
(Vlachopoulos et al 2003). Low ethanol decreases cytosolic
free calcium, an initiator of smooth muscle cell contraction.
We have shown in rat models of essential hypertension that
low ethanol reduced AGEs and platelet cytosolic free
calcium (Vasdev et al 1999). Low ethanol activated sarco/
endoplasmic reticulum uptake of calcium in platelets
(Mitidieri and de Meis 1995) which would lower cytosolic
free calcium concentration. This effect of ethanol on vascular
Figure 4 Antioxidant activity of low ethanol. Free radicals (ROO
-) are reduced (ROOH) by vitamins which become oxidized in the process. These vitamin radicals
are reduced by nicotinamide adenine dinucleotide (NADH) which forms oxidized nicotinamide adenine dinucleotide (NAD+). Ethanol in low concentrations converts
NAD+ back into NADH, via its metabolism to acetate. At this low level, acetate, which is a normal metabolite of glucose and fatty acid metabolism, is further
metabolized in the citric acid cycle.
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dilation/contraction regulators may contribute to its
beneficial cardiovascular effect (Figure 5).
Low alcohol intake increased insulin sensitivity in
humans (Facchini et al 1994; Flanagan et al 2000) and in
rats (Furuya et al 2003). Improving insulin resistance, the
source of excess aldehydes, would limit formation of AGES
and their subsequent hypertensive and atherosclerotic
complications (Figure 5). Since aldehydes and AGEs have
also been shown to inhibit GAPDH (Morgan et al 2002;
Beisswenger et al 2003), likely further exacerbating insulin
resistance, reducing AGE formation may limit the effect of
this cycle. Low ethanol may also work to improve insulin
resistance by lowering plasma free fatty acids and improving
glucose uptake and metabolism (Avogaro et al 2002).
Low ethanol intake has a beneficial effect on lipoprotein
profiles (Figure 5). Low ethanol has been shown to increase
HDL (Facchini et al 1994; De Oliviera e Silva et al 2000;
Ellison et al 2004). This increase may be a result of mediating
the AGE-induced inhibitory effect on reverse cholesterol
transport. In hypertensive patients low ethanol decreased
lipoprotein a (Lp[a]), an independent predictor for
atherosclerosis (Catena et al 2003). It has been suggested
that this may be due to an increase in the transportation rate
of apolipoprotein AI and AII (De Oliviera e Silva et al 2000)
or to an ethanol-induced redistribution of cholesteryl ester
transport proteins between HDL and VLDL (Hannuksela et
al 1996). Chronic low ethanol intake stimulated paraoxonase
activity by upregulating liver paraoxonase mRNA in rats
and humans (Rao et al 2003). Ethanol may also prevent
inhibition of paraoxonase by lowering AGEs.
Implication for treatment
We have suggested that low ethanol intake affords beneficial
cardiovascular effects due to its ability to improve insulin
resistance and its subsequent detrimental effects. However,
due to the addictive nature of alcohol, recommending
ethanol intake at any level may not be prudent. It may be
more appropriate to suggest other agents which act in a
similar fashion and may provide the same beneficial effects
without the complication of addiction. Supplementation with
antioxidants including vitamin C, E, or B6, N-acetylcysteine,
lipoic acid and coenzyme Q10 has been shown to lower
blood pressure in animal models and humans with essential
hypertension (Duffy et al 1999; Singh et al 1999; Vasdev et
al 2000a, 2000b, 2002; Morcos et al 2001; Barrios et al
2002; Boshtam et al 2002). In humans, antioxidants have
also shown a beneficial effect on atherosclerotic endpoints
in several studies (Stampfer et al 1993; Losonczy et al 1996;
Stephens et al 1996). As well, various anti-AGE therapies,
which either prevent or reverse AGE formation, such as
pyridoxamine, thiamine, metformin, alagebrium, or soluble
RAGE have been shown to attenuate hypertension and
atherosclerotic disease (Kislinger et al 2001; Degenhardt et
al 2002; Mizutani et al 2002; Alderson et al 2003; Babaei-
Figure 5 Mechanism of action of low ethanol.Vascular Health and Risk Management 2006:2(3) 273
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Jadidi et al 2003; Midaoui et al 2003; Sakaguchi et al 2003;
Smit and Lutgers 2004; Stitt et al 2004).
Conclusion
In summary, insulin resistance leads to altered glucose and
lipid metabolism. A subsequent increase in AGEs, oxidative
stress, and endothelial dysfunction leads to the development
of hypertension and atherosclerosis. Low ethanol intake
provides cardiovascular beneficial effect primarily through
its ability to increase antioxidant capacity, improving insulin
resistance and decreasing AGEs. Considering the potential
for addiction with ethanol consumption, agents such as
antioxidants which have similar antihypertensive and anti-
atherosclerotic mechanisms, may provide an appropriate
alternative.
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